[HTML][HTML] Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration …
S Rasul, M Hartenbach, T Wollenweber… - European journal of …, 2021 - Springer
Abstract Background and aims [177 Lu] Lu-PSMA-617 radioligand therapy (PSMA-RLT) is a
new therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) …
new therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) …
Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant …
R Sazan, M Hartenbach, T Wollenweber… - … Journal of Nuclear …, 2021 - search.proquest.com
Results Forty-nine (80.3%) patients demonstrated a therapy response in terms of any PSA
decline, while 21 (19.7%) patients showed increase or no changes in their PSA levels …
decline, while 21 (19.7%) patients showed increase or no changes in their PSA levels …
[HTML][HTML] Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration …
S Rasul, M Hartenbach, T Wollenweber… - European Journal of …, 2021 - ncbi.nlm.nih.gov
Results Forty-nine (80.3%) patients demonstrated a therapy response in terms of any PSA
decline, while 21 (19.7%) patients showed increase or no changes in their PSA levels …
decline, while 21 (19.7%) patients showed increase or no changes in their PSA levels …
[引用][C] Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant …
S Rasul, M Hartenbach, T Wollenweber… - European Journal of …, 2020 - elibrary.ru
[PDF][PDF] Prediction of response and survival after standardized treatment with 7400 MBq 177 Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant …
S Rasul, M Hartenbach, T Wollenweber… - 2020 - researchgate.net
Abstract Background and aims [177Lu] Lu-PSMA-617 radioligand therapy (PSMA-RLT) is a
new therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) …
new therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) …
[PDF][PDF] Prediction of response and survival after standardized treatment with 7400 MBq 177 Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant …
S Rasul, M Hartenbach, T Wollenweber… - 2020 - scholar.archive.org
Abstract Background and aims [177Lu] Lu-PSMA-617 radioligand therapy (PSMA-RLT) is a
new therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) …
new therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) …
Prediction of response and survival after standardized treatment with 7400 MBq Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate …
S Rasul, M Hartenbach, T Wollenweber… - European Journal of …, 2021 - inis.iaea.org
[en][177 Lu] Lu-PSMA-617 radioligand therapy (PSMA-RLT) is a new therapy for patients
with metastatic castration-resistant prostate cancer (mCRPC). However, identification of …
with metastatic castration-resistant prostate cancer (mCRPC). However, identification of …
Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant …
S Rasul, M Hartenbach… - … journal of nuclear …, 2021 - pubmed.ncbi.nlm.nih.gov
Background and aims [177 Lu] Lu-PSMA-617 radioligand therapy (PSMA-RLT) is a new
therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). However …
therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). However …
Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant …
S Rasul, M Hartenbach, T Wollenweber… - European Journal of …, 2020 - europepmc.org
Results Forty-nine (80.3%) patients demonstrated a therapy response in terms of any PSA
decline, while 21 (19.7%) patients showed increase or no changes in their PSA levels …
decline, while 21 (19.7%) patients showed increase or no changes in their PSA levels …
Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant …
S Rasul, M Hartenbach… - … Journal of Nuclear …, 2021 - search.ebscohost.com
Abstract Background and aims:[< sup> 177</sup> Lu] Lu-PSMA-617 radioligand therapy
(PSMA-RLT) is a new therapy for patients with metastatic castration-resistant prostate cancer …
(PSMA-RLT) is a new therapy for patients with metastatic castration-resistant prostate cancer …